Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Azambuja, E de"'
Autor:
Condorelli, M, Vos, M De, Fong, S Lie, Autin, C, Delvigne, A, Meerschaut, F Vanden, Wyns, C, Imbert, R, Cheruy, C, Bouziotis, J, Azambuja, E de, Delbaere, A, Lambertini, M, Demeestere, I, De Vos, M, Lie Fong, S, Vanden Meerschaut, F, de Azambuja, E
Publikováno v:
Human Reproduction; Feb2021, Vol. 36 Issue 2, p381-389, 9p
Background: Burnout in health care professionals could have serious negative consequences on quality of patient care, professional satisfaction and personal life. Our aim was to investigate the burnout prevalence, work and lifestyle factors potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::25a695389e6f4da8f51e34d4a95a2091
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3175556
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3175556
Autor:
M.J. Scullion, Bernhard C. Pestalozzi, R. D. Gelber, Otto Metzger, L Hogge, Eileen Holmes, Martine Piccart-Gebhart, Azambuja E de, David Cameron
Publikováno v:
Cancer Research. 71:P4-17
Background: Retrospective studies of HER2−positive metastatic breast cancer (BC) showed an incidence of CNS metastases of 21% to 34%. We investigated the incidence and clinical aspects of CNS relapse (CNS-R) in patients (pts) enrolled in the HERA t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6296dfa379f80f377e46741c382451c3
https://doi.org/10.1158/0008-5472.sabcs11-p4-17-01
https://doi.org/10.1158/0008-5472.sabcs11-p4-17-01
Autor:
G. Viale, Mitchell Dowsett, E Gresko, Otto Metzger, M.J. Piccart, Christos Sotiriou, Marion Procter, R. D. Gelber, Sherene Loi, Brian Leyland-Jones, Azambuja E de
Publikováno v:
Cancer Research. 71:P2-18
Background: Invasive lobular carcinoma (ILC) represents the second most common BC subtype and is often characterized as hormone receptor positive and HER2−negative. However a small subset of ILC is found to be HER2+. Isolated case reports have demo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6440a3d51e3994637ca1ea686bbc8fa1
https://doi.org/10.1158/0008-5472.sabcs11-p2-18-01
https://doi.org/10.1158/0008-5472.sabcs11-p2-18-01
Autor:
F Focant, Hatem A. Azim, E Gresko, Marion Procter, Otto Metzger-Filho, Martine Piccart-Gebhart, Azambuja E de, S. Loibl
Publikováno v:
Cancer Research. 71:P1-12
Background: 1-year of adjuvant trastuzumab (T) is the standard of care in managing patients (pts) with early HER2−positive breast cancer (BC). As T is not known to alter fertility, pts with childbearing potential could become pregnant during or fol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0e9d2cdc6b6d36cfa2c61588ae2469b
https://doi.org/10.1158/0008-5472.sabcs11-p1-12-01
https://doi.org/10.1158/0008-5472.sabcs11-p1-12-01
Autor:
Azambuja, E de1 (AUTHOR) evandro.azambuja@bordet.be, Piccart-Gebhart, M2 (AUTHOR)
Publikováno v:
Annals of Oncology. Jun2019, Vol. 30 Issue 6, p875-877. 3p.
Autor:
Minckwitz G von, Ian Bradbury, Kamal S Saini, G Ross, Azambuja E de, M.J. Scullion, Martine Piccart-Gebhart, J. Baselga
Publikováno v:
Cancer Research. 71:OT1-02
Background Approximately 20% of breast cancer (BC) patients (pts) have HER2−positive tumors. While the adjuvant use of the anti-HER2 humanized monoclonal antibody trastuzumab (T) has been shown to improve disease-free (DFS) and overall survival (OS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f21742ecbd466a88b86d55029258c38
https://doi.org/10.1158/0008-5472.sabcs11-ot1-02-04
https://doi.org/10.1158/0008-5472.sabcs11-ot1-02-04
Autor:
Brandão, M1 (AUTHOR), Caparica, R1 (AUTHOR), Eiger, D1 (AUTHOR), Azambuja, E de1,2 (AUTHOR) evandro.azambuja@bordet.be
Publikováno v:
Annals of Oncology. 2019 Supplement, Vol. 30, px27-x42. 16p. 1 Diagram, 3 Charts.
Autor:
Holmes, E M1 (AUTHOR), Bradbury, I1 (AUTHOR), Williams, L S2 (AUTHOR), Korde, L3 (AUTHOR), Azambuja, E de4 (AUTHOR), Fumagalli, D5 (AUTHOR), Moreno-Aspitia, A6 (AUTHOR), Baselga, J7 (AUTHOR), Piccart-Gebhart, M8 (AUTHOR), Dueck, A C9 (AUTHOR), Gelber, R D10 (AUTHOR) gelber@jimmy.harvard.edu, Team, ALTTO Trial Study (AUTHOR)
Publikováno v:
Annals of Oncology. Sep2019, Vol. 30 Issue 9, p1507-1513. 7p. 2 Charts, 3 Graphs.
Autor:
Poggio, F1, Bruzzone, M2, Ceppi, M2, Pondé, N F3, Valle, G La4, Mastro, L Del5, Azambuja, E de3, Lambertini, M6 matteo.lambertini85@gmail.com
Publikováno v:
Annals of Oncology. Jul2018, Vol. 29 Issue 7, p1497-1508. 12p. 1 Diagram, 5 Charts, 1 Graph.